Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on Clostridium difficile.

Cheleste M Thorpe1, Sherwood L Gorbach

  • 1Department of Geographic Medicine and Infectious Diseases, Tufts-New England Medical Center, 750 Washington Street, Box 041, Boston, MA 02111, USA. cthorpe@tufts-nemc.org.

Current Treatment Options in Gastroenterology
|August 12, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel Synergies and Isolate Specificities in the Drug Interaction Landscape of Mycobacterium abscessus.

Antimicrobial agents and chemotherapy·2023
Same author

Citrobacter rodentium(ϕStx2dact), a murine infection model for enterohemorrhagic Escherichia coli.

Current opinion in microbiology·2021
Same author

Ridinilazole, a narrow spectrum antibiotic for treatment of <i>Clostridioides difficile</i> infection, enhances preservation of microbiota-dependent bile acids.

American journal of physiology. Gastrointestinal and liver physiology·2020
Same author

Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin.

PloS one·2018
Same author

A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2018
Same author

Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin.

The Journal of antimicrobial chemotherapy·2018

Clostridium difficile colitis is increasing in severity due to a virulent, fluoroquinolone-resistant C. difficile strain. Treatment requires a multifaceted approach, including antibiotics, supportive care, and potential immunotherapy for severe cases.

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Epidemiology

Background:

  • Rising incidence and severity of Clostridium difficile colitis globally.
  • Emergence of a hypervirulent, fluoroquinolone-resistant C. difficile strain linked to epidemics.
  • Decreasing efficacy of metronidazole as a first-line treatment.

Purpose of the Study:

  • To outline an aggressive, multifaceted treatment strategy for severe Clostridium difficile colitis.
  • To discuss emerging therapeutic and preventative approaches for C. difficile infections.
  • To highlight the complexity in identifying patients at risk for severe disease.

Main Methods:

  • Review of current treatment protocols for severe C. difficile colitis.
  • Discussion of antibiotic cessation, oral and intravenous vancomycin, metronidazole, and intravenous immunoglobulin.

Related Experiment Videos

  • Consideration of surgical consultation and immunotherapeutic strategies.

    • Main Results:

    • Severe C. difficile colitis management involves antibiotic adjustment, vancomycin, metronidazole, IVIG, and surgical consultation.
    • The role of intravenous immunoglobulin (IVIG) in severe cases is suggested but lacks robust clinical trial data.
    • Active or passive immunization strategies are under investigation to prevent severe outcomes.

    Conclusions:

    • Effective management of severe C. difficile colitis necessitates a comprehensive, multi-pronged strategy.
    • Further research is required to validate the efficacy of IVIG and other immunotherapies.
    • Identifying at-risk populations for severe C. difficile-associated disease remains challenging.